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Abstract
Accurate diagnosis is critical to providing appropriate care in infectious diseases. New 
technologies for infectious disease diagnostics are emerging, but gaps remain in test development 
and availability. The Emerging Infections Network surveyed Infectious Diseases physicians to 
assess unmet diagnostic needs. Responses reflected the urgent need to identify drug-resistant 
infections and highlighted the potential for early diagnosis to improve antibiotic stewardship. 
Information gained from this survey can help inform recommendations for new diagnostic test 
development in the future.
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INTRODUCTION
The importance of diagnostic testing in the management of infectious diseases was recently 
highlighted in the report of the Infectious Diseases Society of America’s (IDSA) 
Diagnostics Task Force1 report: “Better Tests: Better Care: Improved Diagnostics for 
Infectious Diseases.” Similar sentiments are expressed in the report on Antibiotic Resistance 
Threats in the United States2 from the Centers for Disease Control and Prevention (CDC). A 
© 2014 Elsevier Inc. All rights reserved.
Correspondence to be sent to: Anne J. Blaschke, MD, PhD, University of Utah Department of Pediatrics, Division of Pediatric 
Infectious Diseases, P.O Box 581289, Salt Lake City, UT 84158, (801) 581-6791 (ph), (801) 585-3789 (fax), 
anne.blaschke@hsc.utah.edu. Alternate Corresponding Author: Kimberly E. Hanson, MD, MHS, University of Utah Department of 
Pathology, 15 North Medical Drive East, Salt Lake City, UT 84158, (801) 583-2787 ext 3384 (ph), kim.hanson@hsc.utah.edu. 
Conflict of Interest
AJB and KEH have collaborated with BioFire Diagnostics, Inc. (Salt Lake City, UT) on federally-funded projects. AJB has 
intellectual property in and receives royalties from BioFire Diagnostics, Inc. KEH has performed contract work for SanofiPasteur.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Diagn Microbiol Infect Dis. Author manuscript; available in PMC 2016 January 01.
Published in final edited form as:









number of new diagnostic technologies for infectious diseases (ID) are rapidly emerging: 
e.g., broad-range PCR, next-generation sequencing and matrix-assisted laser desorption/
ionization time of flight (MALDI-TOF) mass spectrometry. The reports from the IDSA and 
the CDC highlight deficiencies in current diagnostic methods, and call for approval and 
access to methods that are rapid, available at the point-of-care, use direct-from-specimen 
analysis and demonstrate high levels of sensitivity and specificity across a wide range of 
disease syndromes. The importance of syndrome-based panels (e.g. for central nervous 
system, bloodstream and respiratory tract infections) is highlighted in the IDSA report1. 
Both the IDSA and CDC emphasize the critical need for culture-independent testing for 
specific pathogens and their pattern of susceptibility to antimicrobial agents.
The routine patient contact of participants in the CDC-funded Emerging Infections Network 
(EIN) provides an opportunity for a direct assessment of current diagnostic needs from the 
perspective of care at the bedside. We therefore surveyed EIN members regarding their 
unmet diagnostic needs. The survey results, reported here, have the potential to focus 
advocacy, regulatory, and public health activities designed to hasten clinical application of 
emerging diagnostic technologies.
METHODS
The EIN is a network of infectious diseases physicians in North America that was 
established in 1995 by the CDC to create a provider-based emerging infections sentinel 
network3. EIN members who receive surveys are physician members of IDSA who are 
actively involved in the practice of infectious diseases. This survey was sent electronically 
or via facsimile to all 1,572 physician members in spring 2013.
The survey consisted of brief introductory text and 9 questions (can be viewed at: http://
www.int-med.uiowa.edu/Research/EIN/Unmet_Diagnostic_Needs_Query.pdf). All EIN 
surveys, including this one, include an “opt-out” option which allows members who are not 
involved in the aspect of infectious disease practice being queried to answer “not 
applicable”. For this survey, members were able to respond by email that they were not 
involved in non culture-based diagnostics without answering any specific survey questions.
In the survey, “unmet” needs were defined as testing not available in the respondent’s 
clinical practice, or circumstances where test results are not available in a clinically 
meaningful timeframe. Survey respondents were asked to rank in order from 1 (least 
important) to 6 (greatest need) selected unmet needs. Six syndromes (central nervous system 
infection, community-acquired pneumonia, febrile neutropenia, infectious diarrhea, culture-
negative endocarditis) and six pathogens (drug resistant gram-negative bacilli, methicillin-
resistant Staphylococcus aureus, drug resistant Mycobacterium tuberculosis, molds, 
influenza and HIV resistance) were specifically listed. Free text answers were encouraged.
Respondents were additionally asked to: consider the potential impact of rapid identification 
of specific genetic determinants of antimicrobial resistance on their clinical practice (ranked 
1–5, no impact to high impact); choose a single test not currently available to them that 
would be most helpful; score the importance of various test characteristics (i.e. sensitivity 
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and specificity, turn around time, cost and availability of outcome data supporting test 
benefits) when choosing a new test (ranked 1–5, not important to highly important); and to 
delineate required turn-around-times for various tests in terms of clinical utility. Lastly, 
respondents were asked their opinion regarding whether some infectious diseases diagnostic 
testing is becoming too complicated to be interpreted by non-infectious diseases physicians 
and if there should be “stewardship” for particularly complex or expensive tests.
We used descriptive statistics for analysis and Chi-Square Tests to compare proportions. All 
analyses were conducted using SAS 9.3 (Cary, NC).
RESULTS
A total of 700 respondents (44.5% of EIN physician members) completed the survey; 97 
chose the “opt-out” option by indicating that they did not use non-culture-based diagnostics 
and were excluded. Forty-five percent of respondents estimated that at least 1 out of 4 
patients in their practice are immune compromised. Twenty-three percent of respondents 
were in pediatric practice. As is usual for most EIN surveys, non-respondents were 
significantly more likely than respondents to have less than 15 years of experience in ID 
(p<0.001), to have an adult practice (p <0.01) and to work in a community hospital (p<0.01).
Respondents indicated that their most important pathogen-specific unmet diagnostic need 
was the prompt identification of drug-resistant aerobic gram-negative bacilli (mean score 
4.33 out of 5) (Figure 1A). Identification of drug-resistant M. tuberculosis had the second-
highest score (3.93 out of 5). Additional pathogens mentioned in the open text field 
included: Borrelia burgdorferi, Clostridium difficile, Aspergillus species, Coccidioides 
immitis and human parechovirus. Respondents felt that rapid detection of extended-spectrum 
β-lactamase (ESBL) resistance markers, the Klebsiella pneumoniae carbapenamase (KPC) 
or the presence of mecA would strongly impact patient care (all with mean scores ≥ 4 out of 
5).
The clinical syndrome ranked most highly as in need of improved diagnostics was culture-
negative endocarditis (mean score 3.90 out of 5). Infectious diarrhea was the second-ranked 
syndrome (mean score 3.87 out of 5) (Figure 1B). Other syndromes suggested in the free 
text included: osteomyelitis/septic arthritis, prosthetic joint infections/orthopedic hardware 
infections and hospital- or ventilator-associated pneumonia.
When asked to choose a single test not currently available to them (not available in their 
practice, or not invented yet) that would be most helpful, 18% of 451 members providing a 
response identified pathogen-based testing for respiratory infection (lower and upper 
respiratory tract); 15% requested testing that could distinguish viral from bacterial infection 
and another 15% requested testing for antibiotic resistant organisms, including aerobic gram 
negative bacilli and staphylococci.
Test accuracy and adequate turn-around-time were identified as the most important test 
characteristics (mean scores 4.72 out of 5 and 4.61 out of 5, respectively) when choosing to 
use a new diagnostic test. “Adequate” turn-around-time was categorized as < 1 hour for 
rapid influenza testing (92%), <12 hours for direct detection of bacterial bloodstream 
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infection (89%) and up to 24 hours for identification of drug resistant TB (86%). The 
availability of outcome data supporting the benefits of testing was ranked only slightly 
higher than cost of the testing (4.1 out of 5 vs. 4.07 out of 5).
The majority (67.5%) of respondents felt that some testing is becoming too complex for 
non-infectious diseases physicians, and 79% believed there should be stewardship for 
particularly complicated or expensive tests. Forty-six percent of respondents selected 
multiplex molecular respiratory panels, broad-range PCR testing and antigen-based tests for 
fungal infection as tests that should be restricted or require prior approval.
DISCUSSION
New technologies have improved our ability to accurately and rapidly diagnose many 
infections, but the need for additional advancements is increasingly recognized1,2. This 
survey of practicing ID physicians suggests areas for future test development that mirror 
expert opinion. In particular, physicians report the need for testing that can enhance our 
ability to identify drug-resistant organisms and demonstrate an appreciation for judicious use 
of high-complexity testing through stewardship.
Antibiotic resistant organisms are a serious health threat.2 Overuse of antimicrobials 
contributes to both the rise and persistence of drug resistant organisms, and there is an 
urgent need for strategies to shorten the duration of multidrug empiric therapy4 and to stop 
unnecessary prescribing. Diagnostic tests that can quickly identify specific pathogens are 
critical to antibiotic stewardship efforts that seek to promote narrow-spectrum, targeted 
treatment for infectious illness as opposed to empiric broad-spectrum therapy.4–6 Survey 
respondents consistently ranked highly the identification of resistant organisms with 
emphasis on better testing for multidrug resistant aerobic gram-negative bacilli.
An important caveat pertinent to testing for the genes responsible for resistance in gram-
negative organisms is the complexity of the resistance mechanisms. The absence of ESBLs, 
cephalosporinases, and carbapenemases does not preclude beta-lactam resistance as a result 
of cell wall porin closure and/or activity of efflux pumps.7,8 Molecular test development will 
need to cover a wide range of possible resistance mechanisms, which presents a significant 
challenge. Rapid phenotypic resistance testing may be an alternative approach. Our 
respondents did feel that methods that identified ESBL or KPC resistance mechanisms alone 
would provide useful information even if other mechanisms of resistance were unknown.
In several cases, tests ranked highly as “unmet” needs (for example, rapid resistance testing 
for staphylococci, testing panel for infectious diarrhea) were actually commercially available 
or close to receiving FDA approval at the time the survey was given. This suggests that 
clinicians are not aware of tests that are available or that developed tests desired by 
clinicians are not available to them in their practice. Lack of availability may be due to the 
complexity of the testing strategies, the economics of the laboratory or the absence of 
outcome data that could be used to support adoption of new tests. It is critical that physicians 
advocate for testing to be implemented locally or that send out mechanisms are available if 
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they feel that such testing will positively impact patient care. In addition, it is important that 
laboratories educate physicians about new diagnostic assays that are available.
Testing strategies that utilize new technologies are often more expensive and complex than 
traditional methods.9,10 Physicians are becoming familiar with the concept of “stewardship” 
(interventions designed to improve appropriate use) as associated with antibiotic use11, and 
over half of our survey respondents felt that diagnostic testing could benefit from 
stewardship as well. Diagnostics stewardship could address overuse of testing, guidance 
regarding test selection and interpretation, and implementation of work-flow that insures 
that critical results are received and acted on in a timely manner.
An important component of effective stewardship is an evidence base that can be used to 
guide decisions.11 Outcome and cost-effectiveness data are urgently needed that can impact 
testing at both the patient and the system level.1 Survey respondents ranked availability of 
outcomes data highly as an important characteristic to consider when choosing a new 
diagnostic test.
Our study has limitations. The opinions of non-respondents, those that opted-out and other 
physicians not included in the EIN may be different. Although respondents for any EIN 
survey usually have more years of experience, and a higher percentage of pediatric members 
usually respond than the comparable percentage of members with adult practices, these 
differences potentially may bias the results for this survey. Furthermore, the perspectives of 
physicians in other clinically relevant specialties were not assessed.
As new technologies evolve, it is important to stay focused on developing tests that address 
unmet needs and that conserve, rather than consume, our resources. The call for tests to 
identify resistant aerobic gram-negative bacteria reflects the increasing problems of drug-
resistant infection and limited antibiotic development. Recognition of the importance of 
judicious testing through stewardship also parallels increased awareness of rising healthcare 
costs. Information gained from this survey can help inform recommendations for new 
diagnostic test development in the future.
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• New technologies for infectious disease diagnostics are emerging but gaps 
remain.
• We surveyed Infectious Diseases physicians to assess unmet diagnostic needs.
• New diagnostics to identify drug-resistant organisms are an important unmet 
need.
• Notable gaps are identification of gram negatives and culture-negative 
endocarditis
• Testing stewardship could improve appropriate test use.
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Figure 1. Rank of Unmet Pathogen and Syndrome-Based Needs
Survey respondents were asked to rank specifically listed unmet pathogen and syndrome-
based needs from 1 (least important) to 6 (greatest need).
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